Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

3(33.3%)

Phase 3

1(11.1%)

9Total

Phase 1(5)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05829226Phase 1Completed

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Role: lead

NCT07456800Phase 1Completed

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

Role: lead

NCT06717100Phase 1Completed

Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib

Role: lead

NCT07284602Phase 3Not Yet Recruiting

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT05321420Phase 2Active Not Recruiting

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT04666688Phase 1Completed

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT04243837Phase 2Terminated

LYT-100 in Patients With BCRL

Role: lead

NCT04652518Phase 2Terminated

LYT-100 in Post-acute COVID-19 Respiratory Disease

Role: lead

NCT05129865Phase 1Completed

LYT-300 in Healthy Volunteers

Role: lead

All 9 trials loaded